Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 4Prostatic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Multiple Myeloma 1Lung Neoplasms 1Ewing's Sarcoma Family of Tumors 1Colorectal Neoplasms 1Carcinoma, Adenosquamous 1Carcinoma 1Breast Diseases 1Advanced Non-Hematologic Malignancies 1Advanced Cancer 1

Interventions

Dexamethasone 307Bortezomib 161Lenalidomide 130pomalidomide 112daratumumab 94carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40belantamab mafodotin 31elotuzumab 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × figitumumab × Clear all
NCT01536145 2013-03-15

CP-751,871 Treatment For Patients With Multiple Myeloma

Pfizer

Phase 1 Completed
47 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡